Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + gemogenovatucel-T
- Development stage
- Unknown
- Lead developer
- Gradalis
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intradermal
01
Overview
Durvalumab + gemogenovatucel-T (Vigil) is a combination immunotherapy approach. Durvalumab is a PD-L1 checkpoint inhibitor that blocks the interaction between PD-L1 and its receptors, preventing tumor cells from evading immune detection. Gemogenovatucel-T (Vigil) is a triple-function autologous tumor cell immunotherapy that expresses granulocyte-macrophage colony-stimulating factor (GM-CSF) and decreases expression of furin and downstream TGF-β1 and TGF-β2. This combination therapy aims to enhance anti-tumor immune responses through complementary mechanisms.
- Brand names
- Imfinzi + Vigil
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB2 (Transforming growth factor beta 2)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on durvalumab + gemogenovatucel-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + gemogenovatucel-T.